Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

141. Dapagliflozin/metformin - Benefit assessment according to §35a Social Code Book V

Dapagliflozin/metformin - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 May 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-07 Dapagliflozin/metformin (...) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-07 Version 1.0 Dapagliflozin/metformin – Benefit assessment acc. to §35a SGB V 12 May 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2014

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

142. Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy)

Linagliptin/metformin (Jentadueto) - for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) Final Appraisal Recommendation Advice No: 2114 – July 2014 Linagliptin/metformin (Jentadueto ® ? ) 2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets Submission by Boehringer Ingelheim Ltd/Eli Lilly & Co Ltd Additional note: • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching (...) Services and will be considered for review in three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2114: Linagliptin/metformin (Jentadueto ® ? ) 2.5 mg/850 mg and 2.5 mg/1,000 mg film-coated tablets. July 2014. Recommendation of AWMSG Linagliptin/metformin (Jentadueto ® ? ) is recommended as an option for use within NHS Wales

2014 All Wales Medicines Strategy Group

143. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Full Text available with Trip Pro

Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic (...) review of randomized controlled trials Gao W, Dong J, Liu J, Li Y, Liu F, Yang L, Zhou X, Liao L CRD summary The authors concluded that compared with equal-dosage metformin monotherapy, initial combination of metformin and dipeptidyl peptidase-IV inhibitors was more effective in type 2 diabetes glycaemic control without additional risk of adverse events. Although the authors’ conclusions reflect the results, the varied patients and treatments plus the lack of reporting of trial quality mean

2014 DARE.

144. Saxagliptin + metformin - Diabetes Mellitus, Type 2

Saxagliptin + metformin - Diabetes Mellitus, Type 2 Common Drug Review CDEC Meeting — May 21, 2014 Notice of Final Recommendation — June 20, 2014 Page 1 of 4 © 2014 CADTH CDEC FINAL RECOMMENDATION SAXAGLIPTIN / METFORMIN (Komboglyze — AstraZeneca) Indication: Type 2 Diabetes Mellitus Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that saxagliptin/metformin (Komboglyze) be listed for patients if the following clinical criterion and condition are met: Clinical Criterion (...) : ? Patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and saxagliptin, to replace the individual components of saxagliptin and metformin in these patients. Condition: ? Drug plan costs for the saxagliptin/metformin fixed-dose combination (FDC) should not exceed the combined cost of saxagliptin and metformin administered separately. Reason for the Recommendation: At the submitted price, the saxagliptin/metformin FDC ($2.54 per day) is less

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

145. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Dapagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V. [Dapagliflozin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 220. 2014 Final publication URL Indexing Status Subject indexing assigned

2014 Health Technology Assessment (HTA) Database.

146. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Full Text available with Trip Pro

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone.In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week (...) rates were low. Incidences of genital mycotic infections and AEs related to osmotic diuresis and volume depletion were higher with canagliflozin than placebo/sitagliptin.Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients with T2DM on metformin and pioglitazone over 52 weeks.© 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2014 EvidenceUpdates Controlled trial quality: uncertain

147. Addendum to commission A13-17 (vildagliptin/metformin)

Addendum to commission A13-17 (vildagliptin/metformin) Addendum zum auftrag A13-17 (vildagliptin/metformin) [Addendum to commission A13-17 (vildagliptin/metformin)] Addendum zum auftrag A13-17 (vildagliptin/metformin) [Addendum to commission A13-17 (vildagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG (...) . Addendum zum auftrag A13-17 (vildagliptin/metformin). [Addendum to commission A13-17 (vildagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 189. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Nitriles; Pyrrolidines Language Published German Country of organisation Germany English summary There is no English

2014 Health Technology Assessment (HTA) Database.

148. Addendum to commission A13-03 (sitagliptin/metformin)

Addendum to commission A13-03 (sitagliptin/metformin) Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Addendum (...) zum auftrag A13-03 (sitagliptin/metformin). [Addendum to commission A13-03 (sitagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 187. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformins; Pyrazines; Triazoles Language Published German Country of organisation Germany English summary There is no English language summary available. Address

2014 Health Technology Assessment (HTA) Database.

149. Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Vildagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Vildagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 179. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2014 Health Technology Assessment (HTA) Database.

150. Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 176. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes

2014 Health Technology Assessment (HTA) Database.

151. Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Saxagliptin/Metformin (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Saxagliptin/Metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 167. 2013 Final publication URL

2014 Health Technology Assessment (HTA) Database.

152. Vokanamet - canagliflozin / metformin

Vokanamet - canagliflozin / metformin 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu 20 February 2014 EMA/179391/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Vokanamet International non-proprietary name: CANAGLIFLOZIN / METFORMIN Procedure No. EMEA/H/C/002656/0000 Note Assessment report as adopted (...) by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/179391/2014 Page 2/130 Product information Name of the medicinal product: Vokanamet Applicant: Janssen-Cilag International N.V. Turnhoutseweg 30 B-2340 Beerse BELGIUM Active substance: CANAGLIFLOZIN / METFORMIN HYDROCHLORIDE International Nonproprietary Name/Common Name: CANAGLIFLOZIN / METFORMIN Pharmaco-therapeutic group (ATC Code): A10BD16 Therapeutic indication(s): Canagliflozin/Metformin is indicated

2014 European Medicines Agency - EPARs

153. Xigduo - dapagliflozin / metformin

Xigduo - dapagliflozin / metformin 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 21 November 2013 EMA/620505/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Xigduo International non-proprietary name: DAPAGLIFLOZIN / METFORMIN Procedure No. EMEA/H/C/002672/0000 Note Assessment report as adopted (...) by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/620505/2013 Page 2/105 Product information Name of the medicinal product: Xigduo Applicant: Bristol-Myers Squibb/AstraZeneca EEIG Bristol-Myers Squibb House Uxbridge Business Park Uxbridge UB8 1DH UNITED KINGDOM Active substance: METFORMIN / DAPAGLIFLOZIN International Nonproprietary Name/Common Name: DAPAGLIFLOZIN / METFORMIN Pharmaco-therapeutic group (ATC Code): Drugs used in diabetes

2014 European Medicines Agency - EPARs

154. Invokamet (canagliflozin and metformin hydrochloride)

Invokamet (canagliflozin and metformin hydrochloride) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Invokamet (canagliflozin and metformin hydrochloride) Tablets Company: Janssen Pharmaceuticals, Inc. Application No.: 204353 Approval Date: 8/08/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package

155. Metformin

Metformin USE OF METFORMIN IN PREGNANCY 0344 892 0909 USE OF METFORMIN IN PREGNANCY (Date of issue: September 2017 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Metformin is an antihyperglycaemic biguanide used in the management (...) of type 2 diabetes. It acts by lowering basal and postprandial plasma glucose without stimulating insulin secretion, thereby reducing the risk of hypoglycaemia associated with insulin therapy. Metformin is also used off-label for the treatment of infertility secondary to polycystic ovarian syndrome (PCOS). The available data do not show an increased risk of congenital malformation, spontaneous abortion, preterm delivery, small or large for gestational age infants, perinatal mortality or neonatal

2014 UK Teratology Information Service

156. Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes: The GIPS-III Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes: The GIPS-III Randomized Clinical Trial. Metformin treatment is associated with improved outcome after myocardial infarction in patients with diabetes. In animal experimental studies metformin preserves left ventricular function.To evaluate the effect of metformin treatment on preservation of left ventricular function in patients without diabetes presenting with ST-segment elevation (...) myocardial infarction (STEMI).Double-blind, placebo-controlled study conducted among 380 patients who underwent primary percutaneous coronary intervention (PCI) for STEMI at the University Medical Center Groningen, The Netherlands, between January 1, 2011, and May 26, 2013.Metformin hydrochloride (500 mg) (n = 191) or placebo (n = 189) twice daily for 4 months.The primary efficacy measure was left ventricular ejection fraction (LVEF) after 4 months, assessed by magnetic resonance imaging. A secondary

2014 JAMA Controlled trial quality: predicted high

157. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (Abstract)

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients (...) with uncontrolled type 2 diabetes.We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013. Patients with inadequately controlled type 2 diabetes receiving metformin (≥1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7·0% or greater (≥53 mmol/mol) and 10·0% or lower (≤86 mmol/mol), and body-mass index 45 kg/m(2) or lower were randomly assigned to receive once-weekly dulaglutide (1·5 mg) or once-daily liraglutide

2014 Lancet Controlled trial quality: predicted high

158. Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies

Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies Metformin associated with better cardiovascular outcomes than other glycaemic therapies | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin associated with better cardiovascular outcomes than other glycaemic therapies Article Text Therapeutics Observational study Metformin associated with better cardiovascular outcomes than other

2014 Evidence-Based Medicine

159. Metformin for weight loss in schizophrenia: safe but not a panacea

Metformin for weight loss in schizophrenia: safe but not a panacea Metformin for weight loss in schizophrenia: safe but not a panacea | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin for weight loss in schizophrenia: safe but not a panacea Article Text Pharmacological interventions Metformin for weight loss in schizophrenia: safe but not a panacea Cenk Tek 1 , Lydia Chwastiak 2 Statistics from Altmetric.com What is already

2014 Evidence-Based Mental Health

160. Canagliflozin/metformin - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Canagliflozin/metformin - Benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Canagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-27 (...) Canagliflozin/metformin – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-27 Version 1.0 Canagliflozin/metformin – Benefit assessment acc. to §35a SGB V 13 November 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Canagliflozin/metformin – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)